Breast Cancer Clinical Trial
Official title:
Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib
The goal of this research study is to learn more about pain and other symptoms that patients may experience while receiving chemotherapy treatment with platinum agents, taxanes, and/or bortezomib.
If patient agrees to take part in this study, they will be asked to complete 3
questionnaires, 3 sensory tests, and may be asked to take part in a one-on-one symptom
interview.
Symptom Interview:
Depending on when patient is enrolled in this study, they may take part in a one-on-one
interview with a study staff member. A total of 15 participants will take part in this
interview (5 taking platinum agents, 5 taking taxanes, & 5 taking bortezomib). During the
interview, patient will be asked to describe their symptoms. The interview should take about
20-30 minutes to complete.
The interviews will be digitally recorded, transcribed (typed), and used by researchers to
identify symptoms related to receiving this type of chemotherapy. Researchers will use this
information to design a study questionnaire that focuses on chemotherapy symptoms in the
hands and feet. The digital recordings and typed copies of the interview will be destroyed
after researchers have analyzed the interview data and the study is complete.
Questionnaires & Sensory Tests:
All study participants will complete 3 questionnaires that are designed to collect
information about any pain and/or symptoms patient may have experienced, their general
well-being, and personal information such as age and marital status. One (1) of them is
called a symptom assessment questionnaire and patient be will asked to rate their symptoms
on a scale of 0-10.
All study participants will also complete 3 tests, called sensory tests, that are designed
to help researchers learn how sensitive patient is to things such as cold and touch. These
tests involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs
into holes on a board. Patient will also be asked to mark on computerized drawings the areas
where they experience any pain, numbness, and/or cold sensitivity. A study staff member will
explain how to take the tests and use the computerized drawings in more detail at the time
these tests are performed.
It should take about 20-30 minutes to complete all of the questionnaires and tests.
Additional Sensory Testing:
Out of the 200 participants on this study, 40 participants will be asked to return to the
clinic for additional sensory testing to help researchers learn if the tools used for this
study are working as expected.
This additional testing is designed to help researchers learn how sensitive patient is to
things such as touch, cold, warmth, and a pinprick to the finger, hand, or arm. Patient will
be asked to describe how well they can feel each test, and how much pain they may or may not
feel. This additional testing should take about 60 minutes to complete.
Length of Study:
After patient has completed the interview (if they are asked), 3 questionnaires, and 3
sensory tests their participation on this study will be over. If patient is selected to take
part in the additional sensory testing, their participation on this study will be over after
those tests are complete.
This is an investigational study.
Up to 200 participants will take part in this study. All will be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |